Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer research hub

A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer

This study looks at whether a drug called Nivolumab can help prevent cancer from coming back in people who have had surgery for oesophageal or stomach cancer. It compares Nivolumab to a dummy drug to see if it improves the time patients live without their cancer returning.